Early-Stage GLP-1 Win in Obesity; An Argument for BMI’s Value; Insulin Supply Issues

Participants in a phase I trial lost a placebo-adjusted 6.1% of their body weight after 4 weeks of treatment with the investigational oral GLP-1 receptor agonist CT-996, Roche announced.

JAMA published a review on medications for obesity.

BMI is still “a valuable method” for defining obesity despite its flaws, argued authors of an Annals of Internal Medicine opinion piece.

Abbott plans to use TV ads and guerilla marketing in the U.S. launch of its continuous glucose monitoring device for people without diabetes. (Reuters)

Cumulative exposure to insulin-like growth factor 1 excess may be a predictor of cancer in acromegaly but not in clinically nonfunctioning pituitary adenoma, a longitudinal study suggested. (Journal of Clinical Endocrinology & Metabolism)

Yet another health implication linked with irregular sleep: a higher risk for type 2 diabetes. (Diabetes Care)

Patients are concerned about ongoing insulin supply issues, as insulin companies may consider GLP-1 receptor agonists to be the new moneymakers. (STAT)

The therapeutic potential of modulating gut microbiota for the purpose of mitigating obesity and metabolic diseases deserves further research, according to researchers in the Journal of Clinical Endocrinology & Metabolism.

Novo Nordisk said it’s “disappointed” that the Dutch government decided not to cover semaglutide (Wegovy) for weight loss management under the country’s basic insurance. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.